Primary peritoneal serous adenocarcinoma
MONDO:0006386A rare, serous adenocarcinoma that diffusely involves the pelvic peritoneum seen predominantly in elderly postmenopausal women. Exclusion of serous carcinoma arising from the ovary and fimbrial end of fallopian tube is required to diagnose the above entity.
Also known as: primary peritoneal serous adenocarcinoma
2778 clinical trials for this condition and its sub-types, 36 tagged with Primary peritoneal serous adenocarcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Primary peritoneal serous adenocarcinoma
-
New hope for recurrent ovarian cancer: targeted drug may slow tumor growth
Disease control CompletedThis study tested a drug called trametinib in 260 people with low-grade ovarian or peritoneal cancer that returned or worsened. Trametinib works by blocking certain enzymes that help cancer cells grow. The goal was to see if it works better than standard treatments like hormone t…
Phase 2/3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New drug cocktail targets Hard-to-Treat ovarian and endometrial cancers
Disease control CompletedThis early-stage trial tested two drugs—niraparib and copanlisib—in 31 people with recurrent endometrial, ovarian, peritoneal, or fallopian tube cancer. The goal was to find the safest dose and see how well patients tolerated the combination. Both drugs work by blocking enzymes t…
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Major trial tests if abdominal chemo beats IV for tough cancers
Disease control CompletedThis large Phase III trial tested whether adding the drug bevacizumab to chemotherapy works better when the chemo is given into a vein (IV) or directly into the belly (IP). It involved 1560 people with advanced ovarian, fallopian tube, or peritoneal cancers. The goal was to see w…
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Could a custom vaccine help fight ovarian cancer?
Disease control CompletedThis early-phase trial tested a personalized vaccine made from a patient's own immune cells to see if it is safe for people with advanced ovarian, fallopian tube, or peritoneal cancer. Nineteen participants who had already undergone surgery and chemotherapy received the vaccine. …
Early phase 1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC